|
1
|
Batchelor T and Loeffler JS: Primary CNS
lymphoma. J Clin Oncol. 24:1281–1288. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abrey LE: Primary central nervous system
lymphoma. Curr Opin Neurol. 22:675–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Corn BW, Marcus SM, Topham A, Hauck W and
Curran WJ Jr: Will primary central nervous system lymphoma be the
most frequent brain tumor diagnosed in the year 2000? Cancer.
79:2409–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kadan-Lottick NS, Skluzacek MC and Gurney
JG: Decreasing incidence rates of primary central nervous system
lymphoma. Cancer. 95:193–202. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Campo E, Swerdlow SH, Harris NL, Pileri S,
Stein H and Jaffe ES: The 2008 WHO classification of lymphoid
neoplasms and beyond: Evolving concepts and practical applications.
Blood. 117:5019–5032. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Omuro A, Correa DD, DeAngelis LM,
Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C,
Pentsova E, Grommes CC, et al: R-MPV followed by high-dose
chemotherapy with TBC and autologous stem-cell transplant for newly
diagnosed primary CNS lymphoma. Blood. 125:1403–1410. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rubenstein JL, Hsi ED, Johnson JL, Jung
SH, Nakashima MO, Grant B, Cheson BD and Kaplan LD: Intensive
chemotherapy and immunotherapy in patients with newly diagnosed
primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol.
31:3061–3068. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu J, Sun XF, Qian J, Bai XY, Zhu H, Cui
QU, Li XY, Chen YD, Wang YM and Liu YB: Immunochemotherapy for
primary central nervous system lymphoma with rituximab,
methotrexate, cytarabine and dexamethasone: Retrospective analysis
of 18 cases. Mol Clin Oncol. 3:949–953. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rosenwald A, Wright G, Chan WC, Connors
JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland
EB, Giltnane JM, et al: The use of molecular profiling to predict
survival after chemotherapy for diffuse large-B-cell lymphoma. N
Engl J Med. 346:1937–1947. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shipp MA, Ross KN, Tamayo P, Weng AP,
Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, et
al: Diffuse large B-cell lymphoma outcome prediction by
gene-expression profiling and supervised machine learning. Nat Med.
8:68–74. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang CC, McClintock S, Cleveland RP,
Trzpuc T, Vesole DH, Logan B, Kajdacsy-Balla A and Perkins SL:
Immunohistochemical expression patterns of germinal center and
activation B-cell markers correlate with prognosis in diffuse large
B-cell lymphoma. Am J Surg Pathol. 28:464–470. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mahadevan A, Rao CR, Shanmugham M and
Shankar SK: Primary central nervous system diffuse large B-cell
lymphoma in the immunocompetent: Immunophenotypic subtypes and
Epstein-Barr virus association. J Neurosci Rural Pract. 6:8–14.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aki H, Uzunaslan D, Saygin C, Batur S,
Tuzuner N, Kafadar A, Ongoren S and Oz B: Primary central nervous
system lymphoma in immunocompetent individuals: A single center
experience. Int J Clin Exp Pathol. 6:1068–1075. 2013.PubMed/NCBI
|
|
16
|
Hattab EM, Martin SE, Al-Khatib SM, Kupsky
WJ, Vance GH, Stohler RA, Czader M and Al-Abbadi MA: Most primary
central nervous system diffuse large B-cell lymphomas occurring in
immunocompetent individuals belong to the nongerminal center
subtype: A retrospective analysis of 31 cases. Mod Pathol.
23:235–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Raoux D, Duband S, Forest F, Trombert B,
Chambonnière ML, Dumollard JM, Khaddage A, Gentil-Perret A and
Péoc'h M: Primary central nervous system lymphoma:
Immunohistochemical profile and prognostic significance.
Neuropathology. 30:232–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Momota H, Narita Y, Maeshima AM, Miyakita
Y, Shinomiya A, Maruyama T, Muragaki Y and Shibui S: Prognostic
value of immunohistochemical profile and response to high-dose
methotrexate therapy in primary CNS lymphoma. J Neurooncol.
98:341–348. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kinoshita M, Hashimoto N, Izumoto S, Okita
Y, Kagawa N, Maruno M, Ohnishi T, Arita N and Yoshimine T:
Immunohistological profiling by B-cell differentiation status of
primary central nervous system lymphoma treated by high-dose
methotrexate chemotherapy. J Neurooncol. 99:95–101. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bhagavathi S, Sharathkumar A, Hunter S,
Sung L, Kanhere R, Venturina MD and Wilson JD: Activated B-cell
immunophenotype might be associated with poor prognosis of primary
central nervous system lymphomas. Clin Neuropathol. 27:13–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Levy O, Deangelis LM, Filippa DA, Panageas
KS and Abrey LE: Bcl-6 predicts improved prognosis in primary
central nervous system lymphoma. Cancer. 112:151–156. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng J, Tu P, Shi QL, Zhou HB, Zhou ZY,
Zhao YC, Ma HH and Zhou XJ: Primary diffuse large B-cell lymphoma
of central nervous system belongs to activated B-cell-like
subgroup: A study of 47 cases. Zhonghua Bing Li Xue Za Zhi.
37:384–389. 2008.(In Chinese). PubMed/NCBI
|
|
23
|
Lin CH, Kuo KT, Chuang SS, Kuo SH, Chang
JH, Chang KC, Hsu HC, Tien HF and Cheng AL: Comparison of the
expression and prognostic significance of differentiation markers
between diffuse large B-Cell lymphoma of central nervous system
origin and peripheral nodal origin. Clin Cancer Res. 12:1152–1156.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Camilleri-Broët S, Crinière E, Broët P,
Delwail V, Mokhtari K, Moreau A, Kujas M, Raphaël M, Iraqi W,
Sautès-Fridman C, et al: A uniform activated B-cell-like
immunophenotype might explain the poor prognosis of primary central
nervous system lymphomas: Analysis of 83 cases. Blood. 107:190–196.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Patel B, Chacko G, Nair S, Anandan J,
Chacko AG, Rajshekhar V and Turel M: Clinicopathological correlates
of primary central nervous system lymphoma: Experience from a
tertiary care center in South India. Neurol India. 63:77–82. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mounier N, Briere J, Gisselbrecht C, Emile
JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, et
al: Rituximab plus CHOP (R-CHOP) overcomes BCL-2-associated
resistance to chemotherapy in elderly patients with diffuse large
B-cell lymphoma (DLBCL). Blood. 101:4279–4284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Patel B, Chacko G, Nair S, Anandan J,
Chacko AG, Rajshekhar V and Turel M: Clinicopathological correlates
of primary central nervous system lymphoma: Experience from a
tertiary care center in South India. Neurol India. 63:77–82. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Braaten KM, Betensky RA, de Leval L, Okada
Y, Hochberg FH, Louis DN, Harris NL and Batchelor TT: BCL-6
expression predicts improved survival in patients with primary
central nervous system lymphoma. Clin Cancer Res. 9:1063–1069.
2003.PubMed/NCBI
|
|
30
|
Kreher S, Jöhrens K, Strehlow F, Martus P,
Borowiec K, Radke J, Heppner F, Roth P, Thiel E, Pietsch T, et al:
Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
Neuro Oncol. 17:1016–1021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hashmi AA, Hussain ZF, Faridi N and
Khurshid A: Distribution of Ki67 proliferative indices among WHO
subtypes of non-Hodgkin's lymphoma: Association with other clinical
parameters. Asian Pac J Cancer Prev. 15:8759–8763. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gerdes J, Lemke H, Baisch H, Wacker HH,
Schwab U and Stein H: Cell cycle analysis of a cell
proliferation-associated human nuclear antigen defined by
monoclonal antibody Ki67. J Immunol. 133:1710–1715. 1984.PubMed/NCBI
|
|
33
|
Niikura N, Iwamoto T, Masuda S, Kumaki N,
Xiaoyan T, Shirane M, Mori K, Tsuda B, Okamura T, Saito Y, et al:
Immunohistochemical Ki67 labeling index has similar proliferation
predictive power to various gene signatures in breast cancer.
Cancer Sci. 103:1508–1512. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jovanović MP, Jaković L, Bogdanović A,
Marković O, Martinović VC and Mihaljević B: Poor outcome in
patients with diffuse large B-cell lymphoma is associated with high
percentage of bcl-2 and Ki 67-positive tumor cells. Vojnosanit
Pregl. 66:738–743. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miller TP, Grogan TM, Dahlberg S, Spier
CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani
BN, et al: Prognostic significance of the Ki-67-associated
proliferative antigen in aggressive non-Hodgkin's lymphomas: A
prospective Southwest Oncology Group trial. Blood. 83:1460–1466.
1994.PubMed/NCBI
|
|
36
|
Broyde A, Boycov O, Strenov Y, Okon E,
Shpilberg O and Bairey O: Role and prognositic significance of the
Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol. 84:338–343.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dogan A, Bagdi E, Munson P and Isaacson
PG: CD10 and BCL-6 expression in paraffin sections of normal
lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 24:846–852.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Falini B and Mason DY: Proteins encoded by
genes involved in chromosomal alterations in lymphoma and leukemia:
Clinical value of their detection by immunocytochemistry. Blood.
99:409–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Falini B, Fizzotti M, Pucciarini A,
Bigerrna B, Marafioti T, Gambacorta M, Pacini R, Alunni C,
Natali-Tanci L, Ugolini B, et al: A monoclonal antibody (MUM1p)
detects expression of the MUM1/IRF4 protein in a subset of germinal
center B cells, plasma cells, and activated T cells. Blood.
95:2084–2092. 2000.PubMed/NCBI
|
|
40
|
Rosenwald A, Wright G, Chan WC, Connors
JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland
EB, Giltnane JM, et al: The use of molecular profiling to predict
survival after chemotherapy for diffuse large B-cell lymphoma. N
Engl J Med. 346:1937–1947. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hockenbery D, Nuñez G, Milliman C,
Schreiber R and Korsmeyer SJ: Bcl-2 is an inner mitochondrial
membrane protein that blocks programmed cell death. Nature.
348:334–336. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Goscoyne RD, Adomat SA, Krajewski S,
Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P,
Coldman AJ, Reed JC and Connors JM: Prognostic significance of
BCL-2 protein expression and BCL-2 gene rearrangement in diffuse
aggressive non-Hodgkin' s lymphoma. Blood. 90:244–251.
1997.PubMed/NCBI
|
|
43
|
Mahmoud HM and EI-Sakhawy YN: Significance
of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma.
Hematol Rep. 3:e262011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Krogh-Jensen M, Johansen P and D'Amore F:
Primary central nervous system lymphomas in immunocompetent
individuals: Histology, Epstein-Barr virus genome, Ki-67
proliferation index, p53 and bcl-2 gene expression. Leuk Lymphoma.
30:131–142. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Preusser M, Woehrer A, Koperek O,
Rottenfusser A, Dieckmann K, Gatterbauer B, Roessler K, Slavc I,
Jaeger U, Streubel B, et al: Primary central nervous system
lymphoma: A clinicopathological study of 75 cases. Pathology.
42:547–552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cattoretti G, Chang CC, Cechova K, Zhang
J, Ye BH, Falini B, Louie DC, Offit K, Chaganti RS and Dalla-Favera
R: BCL-6 protein is expressed in germinal-center B cells. Blood.
86:45–53. 1995.PubMed/NCBI
|
|
47
|
Falini B, Bigerna B, Pasqualucci L,
Fizzotti M, Martelli MF, Pileri S, Pinto A, Carbone A, Venturi S,
Pacini R, et al: Distinctive expression pattern of the BCL-6
protein in nodular lymphocyte predominance Hodgkin's disease.
Blood. 87:465–471. 1996.PubMed/NCBI
|
